Other Income	12 Months Ended
Sep. 30, 2021
Other Income
Other Income	Note 4 Other Income Grant income During the year ended September 30, 2021, the Company received $497,931 of a $995,862 research grant awarded by the Michael J. Fox Foundation for Parkinson’s Research. The grant will be used to fund a clinical trial of the Company’s lead compound, ANAVEX^®2-73 related to Parkinson’s disease. The grant income is being deferred when received and amortized to other income as the related research and development expenditures are incurred. During the year ended September 30, 2021, the Company recognized $54,100 of this grant on its statements of operations within grant income. At September 30, 2021 an amount of $443,831 (2020: $0Nil) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to other income. During the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant was received in equal quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome. The grant income was deferred when received and amortized to other income as the related research and development expenditures were incurred. During the year ended September 30, 2021, the Company recognized $ Research and development incentive income Research and development incentive income represents income earned by the Company’s Australian subsidiary, of the Australian research and development incentive credit, (the “ATO R&D Credit”). During the year ended September 30, 2021, the Company recorded research and development incentive income of $4,547,099 (AUD 6,068,993) (2020: $4,375,025 (AUD 6,392,266)) in respect of the ATO R&D Credit for eligible research and development expenses incurred during the year. As a matter of course, the Company may be subject to pre-issue review or audit by the ATO. The Company was notified that the ATO is performing a pre-issue review of the 2020 research and development incentive income return. The Company is responding to questions and requests for information and does not expect an adverse finding.

Other Income

12 Months Ended

Sep. 30, 2021

Note 4 Other Income

Grant income

During the year ended September 30, 2021, the Company received $497,931 of a $995,862 research grant awarded by the Michael J. Fox Foundation for Parkinson’s Research. The grant will be used to fund a clinical trial of the Company’s lead compound, ANAVEX^®2-73 related to Parkinson’s disease.

The grant income is being deferred when received and amortized to other income as the related research and development expenditures are incurred. During the year ended September 30, 2021, the Company recognized $54,100 of this grant on its statements of operations within grant income. At September 30, 2021 an amount of $443,831 (2020: $0Nil) of this grant is recorded as deferred grant income, representing the amount of this grant which has not yet been amortized to other income.

During the year ended September 30, 2017, the Company was awarded grant funding in the amount of $597,886. The grant was received in equal quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.

The grant income was deferred when received and amortized to other income as the related research and development expenditures were incurred. During the year ended September 30, 2021, the Company recognized $

Research and development incentive income

Research and development incentive income represents income earned by the Company’s Australian subsidiary, of the Australian research and development incentive credit, (the “ATO R&D Credit”).

During the year ended September 30, 2021, the Company recorded research and development incentive income of $4,547,099 (AUD 6,068,993) (2020: $4,375,025 (AUD 6,392,266)) in respect of the ATO R&D Credit for eligible research and development expenses incurred during the year.

As a matter of course, the Company may be subject to pre-issue review or audit by the ATO. The Company was notified that the ATO is performing a pre-issue review of the 2020 research and development incentive income return. The Company is responding to questions and requests for information and does not expect an adverse finding.